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BACKGROUND: To elucidate the incidence and mechanisms of sunitinib-induced thyroid atrophy, we investigated serial volumetric and
functional changes, and evaluated histological changes of the thyroid gland in metastatic renal cell carcinoma patients who received
sunitinib.
METHODS: Thyroid volume (by computed tomography volumetry) and thyroid function were measured at baseline, during the
treatment, and at post-treatment periods. Histological evaluation of the thyroid gland was performed in four autopsied patients.
RESULTS: The median reduction rate in thyroid volume at last evaluation during sunitinib treatment was 30% in all 17 patients. The
incidence of hypothyroidism during sunitinib treatment was significantly higher in the high reduction rate group (n¼8; more than 50%
reduction in volume) than in the low reduction rate group (n¼9; less than 50% reduction in volume). Half of the patients in the high
reduction rate group exhibited a transient thyroid-stimulating hormone suppression, suggesting thyrotoxicosis during sunitinib
treatment. Histological evaluation demonstrated atrophy of thyroid follicles and degeneration of follicular epithelial cells without
critical diminution of vascular volume in the thyroid gland.
CONCLUSION: Thyroid atrophy is frequently observed following sunitinib treatment and may be brought about by sunitinib-induced
thyrotoxicosis or the direct effects of sunitinib that lead to degeneration of thyroid follicular cells.
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Sunitinib malate (SUTENT, Pfizer Inc., New York, NY, USA) is an
oral, multitargeted tyrosine kinase inhibitor of vascular endothelial
growth factor receptors, platelet-derived growth factor receptors,
stem cell factor receptor (c-KIT), and is rearranged during
transfection. It has been approved for the treatment of gastro-
intestinal stromal tumour and metastatic renal cell carcinoma (RCC).
Single-agent sunitinib showed unprecedented antitumour activity in
two phase II trials of patients with metastatic RCC, demonstrating an
objective response rate of 33% (Motzer et al, 2006a,b). Furthermore,
sunitinib demonstrated superior first-line efficacy over IFN-a,w i t h
significantly greater progression-free survival (PFS) (Motzer et al,
2007, 2009). On the basis of these results, sunitinib is one of the
standard drugs for treatment-naı ¨ve RCC in the National Compre-
hensive Cancer Network treatment guidelines.
Although sunitinib is a potent drug, it is relatively toxic and is
reported to have several treatment-related adverse events, such as
myelosuppression, hypertension, hand-foot syndrome, and
diarrhoea (Motzer et al, 2009; Theou-Anton et al, 2009). Of these,
hypothyroidism has recently been recognised as one of the most
frequently observed adverse events and a clinically relevant
toxicity of sunitinib. In a prospective study by Desai et al,
hypothyroidism developed in 15 (36%) of 42 patients with
gastrointestinal stromal tumour treated with sunitinib for a
mean of 50 weeks (Desai et al, 2006). Rini et al reported that
hypothyroidism occurred in 56 (85%) of 66 patients with
metastatic RCC at a median of two cycles of sunitinib treatment
(Rini et al, 2007). Although the mechanism behind this complica-
tion remains unclear, it is considered that treatment with
levothyroxine sodium can control subclinical and overt hypo-
thyroidism induced by sunitinib.
Sunitinib is reported to induce another type of toxicity of the
thyroid, thyroid atrophy, in some patients. In the study by Desai
et al, severe thyroid atrophy occurred in two patients who
experienced sunitinib-induced thyrotoxicosis, which was probably
due to destructive thyroiditis (Desai et al, 2006). On the other
hand, Mannavola et al reported that, in 11 patients with
gastrointestinal stromal tumour, whose thyroids were evaluated
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sby ultrasonography, no changes in volume and/or echographic
pattern were recorded during sunitinib treatment (Mannavola
et al, 2007). Thus, no consensus has yet been reached on whether
sunitinib induces thyroid atrophy during the treatment. Further-
more, there are no data on histological changes in the thyroid
gland in patients who received sunitinib. To elucidate the
incidence and the underlying mechanisms of thyroid atrophy, we
investigated the serial volumetric and functional changes and
evaluated histological changes of the thyroid gland in patients with
metastatic RCC who received sunitinib.
MATERIALS AND METHODS
Patients
A total of 17 patients with metastatic RCC were enrolled in a
prospective observational study. In total, 12 patients were treated
in a phase II trial investigating single-agent sunitinib therapy
in Japanese patients with metastatic RCC (Uemura et al, 2010).
The remaining five patients were enrolled after April 2008 as a
cohort of a post-marketing surveillance study. Patients having
a history of medical treatment for thyroid disease and those who
underwent sunitinib therapy for less than 4 weeks were excluded
from the present study.
In most patients, sunitinib was administered at a starting dose
of 50mg orally, once daily, in the morning, without regard to
meals, in repeated 6-week cycles according to Schedule 4 out of 2
(4 weeks on treatment, followed by 2 weeks off). Patients were
monitored for toxicity, and doses were adjusted following
individual patient tolerance according to the following protocol.
Doses were reduced to 37.5mg per day in cases of treatment-
related grade 43 adverse events, and additionally to a minimum
dose of 25mg per day if toxicities persisted. Treatment was
continued until one of the following occurred: disease progression;
requirement for additional anticancer treatment; development of
left ventricular dysfunction; or treatment withdrawal.
Tumour assessments were based on the Response Evaluation
Criteria in Solid Tumours (Therasse et al, 2000), with computed
tomography (CT) obtained before treatment and on day 1 of
treatment cycles. All patients gave written informed consent.
The present study was approved by the institutional review board
at two institutions and was conducted in accordance with the
International Conference on Harmonization Guidelines for Good
Clinical Practice.
Evaluation of thyroid function
The thyroid function test (TFT) was assessed at baseline and on
day 1 of each treatment cycle in all but one patient, for whom the
collection of a blood sample at baseline was not carried out. As a
TFT, we measured serum TSH (thyroid-stimulating hormone;
reference range 0.38–4.31mIUl
–1), free triiodothyronine
(reference range 2.1–3.8pgml
–1), and free thyroxine ( reference
range 0.82–1.63ng per 100ml). A TFT was always carried
out before performing a CT scan with iodium contrast. In
some patients, antithyroglobulin antibody (reference range
0–13.6IUml
–1) and antithyroid peroxidase antibody (reference
range 0–3.2IUml
–1) were assessed.
Subclinical hypothyroidism is defined as serum TSH above
the upper limit of normal values, with fT4 within normal limits
at baseline and on day 1 of each cycle. Overt hypothyroidism
is defined as low serum fT4, together with elevated TSH.
Thyroid hormone replacement therapy using levothyroxine
sodium was initiated in patients with at least two consecutive
serum TSH measurements 410mIUl
–1 or with any symptoms
compatible with hypothyroidism according to the recommenda-
tion in Desai et al (2006).
Measurement of thyroid gland volume with CT scan
In all patients, thyroid volume was measured serially by CT
volumetry on a cervical-pelvic CT scan, which was evaluated
every 1 or 2 cycles to assess tumour response. CT volumetry was
performed by two radiologists (TK and HI) who had no clinical
information on thyroid function, using a commercially available
workstation (ZIOSOFT, ZIOSOFT Inc., Tokyo, Japan) (Kato et al,
2009). With ZIOSOFT, three-dimensional reconstruction images
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Figure 1 Measurement of thyroid gland volume using CT scan. A cross-sectional image (A) and three-dimensional (3D) reconstruction image (B) of the
thyroid gland in CT scan with contrast at baseline in patient 5 (thyroid volume 7.8ml). A cross-sectional image (C) and 3D reconstruction image (D)o f
the thyroid gland in the same patient 15 months after the start of sunitinib treatment (thyroid volume was 1.2ml).
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sof thyroid glands were created using contrast-enhanced CT images
of the renal parenchymal phase with a slice thickness of 5mm
(Figure 1A). After creating three-dimensional reconstruction
images of thyroid glands (Figure 1B), the volume of thyroid
glands was obtained. By CT volumetry, the volume of thyroid
gland in patient 5 (before sunitinib treatment) was measured to
be 7.8ml. Figures 1C and D showed a cross-sectional image and
a three-dimensional reconstruction image of the thyroid gland,
respectively, 15 months after the start of sunitinib treatment in the
same patient (thyroid volume¼1.2ml).
Histological evaluation of thyroid gland at autopsy
Histological evaluation of the thyroid gland was performed in
the four patients who received sunitinib and subsequently died
of progressive disease, and in a 57-year-old male patient who died
of cardiac attack. The patient who died of cardiac attack was never
administered sunitinib. Two pathologists (NO and AI), who had no
clinical information on thyroid function, evaluated the haema-
toxylin–eosin (HE)-stained specimens of the thyroid glands
obtained from the four autopsied patients. Furthermore, immuno-
histochemistry with antibody to CD34 was undertaken to analyse
thyroidal capillarisation and arterialisations.
Statistical analysis
Groups of subjects were compared using the Mann–Whitney
U-test (continuous variables) or using Pearson’s w
2-test or
Fischer’s exact test (discrete variables). The PFS was defined as
the interval from the start of sunitinib treatment until confir-
mation of disease progression or death. The PFS was evaluated by
the Kaplan–Meier method with significance determined using the
log-rank test. For all statistical analyses, Po0.05 was regarded as
statistically significant.
RESULTS
The backgrounds of the 17 patients are summarised in Table 1. The
median age was 62 years (range 23–78). Nine patients (53%) had
undergone previous treatment with IFN-a. At the time of final
analysis, patients had received a median of six cycles of sunitinib
treatment (range 1–23). The objective response rate by Response
Evaluation Criteria in Solid Tumours was 53%, with one (6%)
and eight patients (47%) achieving confirmed complete response
and confirmed partial response, respectively. Stable disease for
6 months or longer was also obtained in three patients (18%).
Median PFS of all 17 patients was 11.9 months. In terms of
the TFT at baseline, 12 patients had no abnormal TFT and four
patients showed subclinical hypothyroidism. The median serum
TSH concentration at baseline was 1.63mIUl
–1(range 0.53–10.14).
There was no significant difference in serum TSH concentration
(meanþs.d.) at baseline between patients who received IFN-a and
those who did not (1.69þ0.87 vs 5.22þ4.19, P¼0.244). Thyroid
autoantibodies, antithyroglobulin and antithyroid peroxidase
antibodies were not detected in any of the six patients assessed, of
whom two patients had subclinical hypothyroidism and the others
showed euthyroid at baseline. No patient had any symptoms
suggesting hypothyroidism at entry.
With regard to thyroid function impairment during treatment
with sunitinib, nine patients (53%) developed hypothyroidism and
all but one patient (patient 8) received an appropriate dose of
levothyroxine sodium (50–150mg per day). Of them, four patients
experienced a transient TSH suppression suggesting thyrotoxicosis
before the development of overt hypothyroidism. The remaining
eight patients retained euthyroid status throughout treatment
with sunitinib, with a median of two cycles (range 1–6). All four
patients with subclinical hypothyroidism at baseline developed
overt hypothyroidism during sunitinib treatment. In the 12
patients with euthyroid at baseline, hypothyroidism occurred in
four patients and eight patients retained their euthyroid status.
These results suggest that hypothyroidism is likely to occur in
patients with subclinical hypothyroidism at baseline, than in those
with euthyroid (P¼0.083).
In 17 patients evaluated in the present study, the median thyroid
volume at baseline was 13.6ml (range 5.8–20.2ml). There was no
difference in thyroid volume (meanþs.d.) at baseline between
patients who received IFN-a previously and those who did not
(13.99þ5.39 vs 13.50þ4.17ml, P¼0.810). As dispersion of
thyroid volume at baseline was shown among the patients, the
changes in thyroid volume were evaluated as the rate of reduction
in thyroid volume at each measurement during treatment with
Table 1 Baseline demographic and clinical characteristics of 17 patients
Thyroid autoantibody At baseline During sunitinib-Tx
Patient
Gender/age
(year)
Pre-Tx with
IFN/duration
(months)
Total
cycle of
sunitinib
Best
response
by sunitinib
Thyroglobilin
antibody
(IUml
–1)
TPO
antibody
(IUml
–1)
Thyroid
volume
(ml)
TSH
(mIul
–1) Status
Thyroid
volume
(ml)
TSH
(mIul
–1) Status
1 F/44 No 9 PR o0.15 o0.15 18.5 5.06 Hypo 8 33.15 Hypo
a
2 F/62 No 6 PR o0.15 o0.15 8.3 1.6 Eu 2.4 117.53 Hypo
a
3 M/65 No 23 CR — — 17.3 Unknown 1.1 137.13 Hypo
a
4 M/64 No 11 SD — — 10.6 9.43 Hypo 0.4 230.89 Hypo
a
5 M/69 Yes/6 10 PR o0.15 o0.15 7.8 3.62 Eu 1.2 27.23 Hypo
6 F/56 Yes/3 20 PR — — 11.6 1.86 Eu 1.7 42.53 Hypo
7 F/59 No 18 PR — — 18.2 10.14 Hypo 6.6 19.8 Hypo
8 F/66 No 16 PR 14.3 0.61 Eu 6.8 4.69 Hypo
9 M/52 Yes/6 6 PR — — 21 1.29 Eu 22 3.06 Eu
10 F/23 No 2 PD o0.15 o0.15 8.8 8.65 Hypo 7.9 12.72 Hypo
11 M/65 Yes/24 3 PR o0.12 o0.05 13.6 1.66 Eu 13 3.71 Eu
12 M/55 Yes/3 2 PD — — 11.4 0.84 Eu 9.5 3.91 Eu
13 M/64 No 2 PD — — 12 1.07 Eu 10 3.93 Eu
14 M/78 Yes/6 2 SD — — 20.2 2.24 Eu 19.2 2.3 Eu
15 F/59 Yes/6 1 PD o0.12 o0.05 5.8 1.49 Eu 2.8 3.14 Eu
16 M/76 Yes/20 4 SD — — 15.6 0.65 Eu 14 3.51 Eu
17 M/45 Yes/2 1 PD — — 18.9 1.57 Eu 20.9 1.73 Eu
Abbreviations: CR¼complete response; Eu¼euthyroid; Hypo¼hypothyroidism; PD¼progressive disease; PR¼partial response; SD¼stable disease; TPO¼thyroid
peroxidase; TSH¼thyroid stimulating hormone; Tx¼treatment.
aEvidence of thyrotoxicosis before experiencing hypothyroidism.
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Figure 2 Serial changes in thyroid volume and serum TSH level in the high reduction rate group (n¼8). The four patients experienced a transient
TSH suppression suggesting thyrotoxicosis before the development of hypothyroidism (A). A maximum suppression level of serum TSH and duration
of TSH suppression were 0.03mIUl
–1and 28 days, 0.05mIUl
–1and 14 days, 0.08mIUl
–1and 28 days, and 0.03mIUl
–1and 14 days, in patients 1, 2, 3, and
4, respectively. The remaining four patients did not show signs of thyrotoxicosis (B). Bold lines delineate the change of thyroid gland volume during sunitinib
treatment and dotted lines demonstrate serial change of serum TSH level measured at day 1 of each cycle. %, the development of thyrotoxicosis. .,
the start of levothyroxine. TSH, thyroid-stimulating hormone.
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ssunitinib relative to that at baseline. The median reduction rate
was 30% at the last evaluation during sunitinib treatment (median
six cycles, range 1–23 cycles). On the basis of the reduction rate in
thyroid volume, we could clearly stratify the patients into two
groups: the high reduction rate group (more than 50% reduction;
eight patients) and the low reduction rate group (less than 50%
reduction; nine patients). The median reduction rate of thyroid
volume and median thyroid volume at the last evaluation during
sunitinib treatment were 78% (range 52–95) and 2.1ml (range
0.4–8.0), respectively, in the high reduction rate group. The serial
changes of thyroid volume and serum TSH level in each patient of
the high reduction rate group are shown in Figures 2A and B. The
median reduction rate of thyroid volume and median thyroid
volume at the last evaluation during sunitinib treatment were 10%
(range 0–30) and 13.0ml (range 2.8–20.9), respectively, in the low
reduction rate group (Figure 3). Patient characteristics of the two
groups are listed in Table 2. The patients of the high reduction rate
group received significantly more cycles of sunitinib treatment and
had a significantly higher response rate than the patients of the low
reduction rate group. Furthermore, median PFS was significantly
longer in the former than in the latter. Although there was
no significant difference in the incidence of subclinical hypo-
thyroidism at baseline between the two groups, the incidence
of hypothyroidism during sunitinib treatment was significantly
higher in the high reduction rate group (100%) than in the low
reduction rate group (11%). In addition, four of eight patients in
the high reduction rate group exhibited signs of thyrotoxicosis
during sunitinib treatment. The maximum TSH value during
sunitinib treatment was also significantly higher in the high
reduction rate group.
Of 17 patients evaluated in the present study, six have continued
to receive sunitinib treatment, whereas sunitinib was stopped in
11 patients because of disease progression. In the latter group, four
patients died of cancer in the period after the discontinuation
of sunitinib therapy. We evaluated the changes in TSH value and
thyroid volume in four of the remaining seven patients who
underwent subsequent therapy. No increase in thyroid volume was
observed in two patients of the high reduction rate group during
sunitinib treatment. These two patients experienced overt hypo-
thyroidism with a profound elevation in TSH (326mIUl
–1,
123mIUl
–1) after the discontinuation of sunitinib and levo-
thyroxine sodium, in accordance with the suggestion made by
Mannavola et al (2007). On the other hand, changes in thyroid
volume and TSH value did not occur in the two patients belonging
to the low reduction rate group.
We also evaluated histological changes in the thyroid gland in
the four autopsied patients. Although atrophy of thyroid follicles
and degeneration of follicular epithelial cells were observed in all
four patients, two patients (cases 2 and 5) of the high reduction
rate group who received sunitinib for a long period had more
marked changes in the thyroid gland than the two patients (cases
12 and 15) who underwent short-term treatment of sunitinib who
belonged to the low reduction rate group (Figure 4). In the thyroid
glands without atrophy, vessels were distributed around the
follicles. On the other hand, the mesh distribution of vessels was
destroyed with destruction of follicles in the two patients who
belonged to the high reduction rate group. However, the volume
of vessels in the thyroid gland was relatively well preserved even in
the two patients with marked thyroid atrophy (Figure 5).
DISCUSSION
The present study revealed that sunitinib can induce a reduction in
thyroid volume, thyroid atrophy, as well as hypothyroidism. It is
well known that hypothyroidism is frequently associated with
sunitinib treatment (Desai et al, 2006; Mannavola et al, 2007;
Rini et al, 2007; Wolter et al, 2008). In the present study, about half
of the patients evaluated developed hypothyroidism after a median
of two cycles of treatment. Sunitinib-induced hypothyroidism is
common in Japanese and Caucasian patients. On the other hand,
whether thyroid atrophy is caused by sunitinib treatment has
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Figure 3 Serial changes in thyroid volume in the low reduction rate
group (n¼9).
Table 2 Patient characteristics upon stratification into two groups by the
rate of reduction in thyroid volume
High reduction
rate group
Low reduction
rate group P-value
Gender
Female/male 5/3 2/7 0.234
Age, years
Median (range) 63 (44–69) 59 (23–78) 0.797
Sunitinib Tx, cycles
Median (range) 13.5 (6–23) 2 (1–6) 0.001
ORR
CR/PR 7 2
SD 1 2
PD 0 5 0.012
50% PFS, months Not reach(X14.9) 2.3 0.004
Thyroid status at baseline
Hypothyroidism 3 1
Euthyroid 4 8
Unknown 1 0 0.243
TSH at baseline, mIUl
–1
Median (range) 3.62 (0.61–10.14) 1.57 (0.52–8.65) 0.314
Thyroid volume at baseline, ml
Median (range) 13.0 (7.8–18.5) 13.6 (5.8–21.0) 0.797
Thyroid status during
Sunitinib-Tx
Hypothyroidism 8
a 1
Euthyroid 0 8 0.001
Maximum TSH during
Sunitinib-Tx, mIUl
–1
Median (range) 37.84 (4.69–230.89) 3.51 (1.73–12.72) 0.001
Supplement of L-T4
During sunitinib-Tx 7 1 0.008
Abbreviations: CR¼complete response; ORR¼objective response rate;
PD¼progressive disease; PFS¼progression-free survival; PR¼partial response;
SD¼stable disease; TSH¼thyroid stimulating hormone; Tx¼therapy.
aFour
patients experienced hyperthyroidism before hypothyroidism.
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sremained unclear. To clarify the actual effect of sunitinib on the
thyroid gland, we measured serial changes in thyroid volume and
evaluated histological changes in the thyroid gland in patients who
received sunitinib.
Although the size of the thyroid gland is generally evaluated by
ultrasonography, we measured it by CT volumetry on cervical-
pelvic CT scans. Although there is the problem of radiation
exposure in CT volumetry, unlike in ultrasonographic evaluation,
operator-dependent bias for the measurement of thyroid volume
may be small in CT volumetry (Nygaard et al, 2002). The median
thyroid volume measured by CT volumetry in the 17 patients
before sunitinib treatment was 13.6ml. Furthermore, thyroid
volume at baseline was not affected by previous IFN-a treatment.
Lee et al recorded a thyroid volume of 17.5þ6.6ml by CT
measurement in their study (Lee et al, 2006). The standard volume
of thyroid gland in adults has been reported as 13–18ml, and the
baseline volume in our patients could be considered as equivalent
to this adult standard (Langer, 1989).
In patients receiving sunitinib, a serial reduction in thyroid
volume occurred in 8 of the 17 patients evaluated. There have been
a few studies on changes in thyroid size in patients receiving
sunitinib treatment. Desai et al reported that two patients with
destructive thyroiditis had marked thyroid atrophy that caused
hypothyroidism (Desai et al, 2006). More recently, Rogiers et al
reported that marked shrinkage of thyroid volume during
treatment with sunitinib was observed in two RCC patients with
a preexisting nodular thyroid gland (Rogiers et al, 2010). On the
other hand, Mannavola et al reported that there was no evidence
of thyroid atrophy in patients undergoing sunitinib treatment
(Mannavola et al, 2007). It is questionable whether their
observation period was long enough, as our study showed that a
reduction in thyroid volume of more than 50% occurred in most
patients who received more than six cycles of treatment. All the
eight patients with more than 50% reduction in thyroid size had
hypothyroidism, and half of them developed it after a transient
TSH suppression, suggesting thyrotoxicosis. From the data on
thyroid autoantibodies, a transient TSH suppression in two
patients does not appear to result from autoimmune-mediated
hyperthyroidism. Furthermore, we have to consider the possibility
that thyrotoxicosis might be brought about by the iodine contrast
medium that was used during the CT scan. However, the effect of
the iodine contrast medium on the development of thyrotoxicosis
does not appear to be too strong because a TFT was carried out
before performing a CT scan in all patients. These results suggest
that thyrotoxicosis, which was induced by sunitinib itself, would be
one of the mechanisms that result in thyroid atrophy.
To clarify the effects of sunitinib on the thyroid gland and the
mechanism underlying thyroid atrophy, a histological evaluation
of the thyroid gland was carried out in patients who underwent
autopsy. To the best of our knowledge, histological examination of
the thyroid gland has not been reported in patients who received
sunitinib. We found that there was less damage to the blood supply
of the thyroid gland, but there were atrophic thyroid follicles and
degeneration of follicular epithelial cells. These changes were
× 100
Figure 4 Histological changes in the thyroid gland. (A) The thyroid gland obtained from the patient who received sunitinib for 15 months (patient 5).
The patient underwent best supportive care for 6 months after the discontinuation of sunitinib therapy and no change in thyroid gland volume was observed.
(B) The thyroid gland obtained from the patient who received sunitinib for 2 months (patient 12). The patient died of cancer 1 month after discontinuation
of sunitinib therapy. (C) The thyroid gland obtained from the patient who died of cardiac attack without a past history of thyroidal disease.
× 100
Figure 5 Vascular distribution of the thyroid gland. (A) The thyroid gland obtained from the patient who received sunitinib for 15 months (patient 5).
(B) The thyroid gland obtained from the patient who received sunitinib for 2 months (patient 12). (C) The thyroid gland obtained from the patient who
died of cardiac attack.
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spronounced in patients with severe thyroid atrophy after long-
term sunitinib treatment. The patients who underwent received
short-term treatment without changes in thyroid volume also
showed atrophic thyroid follicles and degeneration of follicular
epithelial cells. Kamba et al reported that a loss of thyroid
homeostasis was associated with inhibition of vascularisation by
a tyrosine kinase inhibitor in a mouse model and that this might
be one of the causes of hypothyroidism and thyroid atrophy
(Kamba et al, 2006). Makita et al described the RCC patient who
displayed overt hypothyroidism with an atrophic thyroid during
on-periods in the sunitinib treatment cycles and who showed
a recovery of thyroid size during off-periods (Makita et al, 2010).
They speculated that thyroid function and volume depended on
vascularity, which was negatively regulated by sunitinib. On the
other hand, Mannavola et al demonstrated that there was no
reduction in thyroid blood flow in patients receiving sunitinib as
shown in ultrasonographic evaluation with colour Doppler, a
finding that supports our results (Mannavola et al, 2007). Salem
et al showed that sunitinib functions on the thyroid gland by
inhibiting the growth of FRTL-5 thyroid cells in a time-related and
dose-related manner (Salem et al, 2008). The degeneration of
thyroid follicular cells revealed by our study may indicate a direct
effect of sunitinib on these cells.
We also examined whether thyroid volume increased after
discontinuation of sunitinib. However, there were no patients
who showed an increase in thyroid volume after discontinuation.
Furthermore, two patients developed a marked elevation in serum
TSH and symptoms of hypothyroidism after discontinuation of
both sunitinib and levothyroxine sodium. Mannavola et al claimed
that patients with hypothyroidism caused by sunitinib treatment
would improve spontaneously after cessation of treatment with
sunitinib and levothyroxine sodium (Mannavola et al, 2007).
However, our results suggest that hypothyroidism associated with
severe thyroid atrophy caused by sunitinib may be irreversible,
at least during a short-term follow-up.
The present study demonstrated that sunitinib causes not only
hypothyroidism but also thyroid atrophy in RCC patients who
receive the drug over a long period, and that this can result in
irreversible hypothyroidism. Possible causes for this are consi-
dered to be sunitinib-induced thyrotoxicosis in some patients and
a direct effect of sunitinib that leads to degeneration of thyroid
follicular cells in others.
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